Clinically & Haematological and Biochemical Profile of COVID-19 Patients with and without co Morbidities
Abstract
The pandemic outbreak of novel coronavirus disease (covid-19) was initially noticed in a seafood market in Wuhan city in China in mid-December, 2019, has spread to 215 countries worldwide. 2020 January 7th and was temporally named 2019 n-cov.
Coronavirus belongs to a large family of virus that causes illness ranging from the common cold to more severe disease, A noval coronavirus is a new strain that has not been previously identified in humans on January 30th, 2020 declared the noval coronavirus outbreak of public health emergency of international concern (PHEIC). At that time there were 98 cases and no death in 18 countries outside china.
The official name covid-19 and SARS –COV2 was issued by the WHO on 11th February 2020 Viruses are named based on their genetic structure to facilitate the development of the diagnostic test, Vaccines, and mediums. Virologists and the wider scientific committee do this work, so the virus is are named by the international committee on taxonomy of viruses.
A recent review of the survival of the human coronavirus on the surface found large variability ranging from 2 hours to 9 days. The survival time depends on a number of factors, including the type of surface, temperature, relative humidity, and a specific strain of viruses.
March 11th, 2020, the rapid increase in the number of cases outside china. 118000 cases had been reported in 114 countries and 4291 deaths had been reported.
Middle of the march 2020 corona outbreak could be characterized by “Pandemic” reporting over 40108 globally confirmed cases. As of 28th April 2020, 63% of global mortality from the virus.
The impact of the disease on the world has been staggering both from public health and economic perspective. we evaluated whether prior or active coronavirus infection influenced hematological, Biochemical, and Clinical parameters of such patients. But active corona fever resulted in a higher hospitalization rate. Our data support the nation that SARS- COV-2 and comorbidity weather affects an important percentage of covid-19 patients and leads to worse parameters, requiring greater attention from health authorities.
References
Li, X. Guan, P. Wu, et al. Early transmission dynamics in wuhan, China, of novel corona virus –infected pneumonia new England journal of medicine, 382 (2020). pp. 1199-207, doi: https://doi.org/10.1056/nejmoa2001316
L. Sheng, X. Wang, N. Tang, et al. clinical characteristics of moderate and severe cases with COVID-19 in Wuhan, China: a retrospective study clinical and Experimental medicine (2020), doi: https://doi.org/10.1007/s10238-020-00662-z
R. Kumar, V. Singh, A. Mohanty, Y. Bahurupi, P.K. Gupta Corona health -care warriors in india: Knowledge, attitude, and practices during COVID-19 outbreak J Educ health promot, 10 (44) (2021), pp. 1-8, doi: https://doi.org/10.4103/jehp.jehp_524_20
D. Wang, B. hu, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel corona virus- infected pneumonia in wuhan, China JAMA, 323 (2020), pp. 1061—1069, doi: https://doi.org/10.1001/jama.2020.1585
J. -F. Gautier, Y. Ravussin A new symptom of COVID -19: loss of taste and smell obesity (2020), p. 848
World Health organization world health organization statement on the second meeting of the international health regulations (2005) Emergency committee regarding the outbreak of novel Corona virus (2019-nCoV) (2020) https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
J. Lu, S. Hu, R. Fan, et al. ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) During the early stage of outbreak in wuhan medRxiv China (2020) p. 2020.02.20.20025510. doi: https://dx.doi.org/10.2139/ssrn.3543603
J. Liu, Y. Liu, P. Xiang, et al. Neutrophil –to- Lymphocyte ratio predicts severe illness patients with 2019 medRxiv Novel Corona virus in the Early Stage (2020) P. doi: https://doi.org/10.1186/s12967-020-02374-0
D. Wang, R. Li, J. Wang, et al. Correlation analysis between disease Severity and Clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: A descriptive study BMC infectious Disease, 20 (2020), p. 519, doi: https://doi.org/10.1186/s12879-020-05242-w
S. Tian, H. Liu, M. Liao, et al. Analysis of mortality in patients with COVID -19: Clinical and laboratory Parameters Open Forum infectious Disease (2020), p. 7, doi: https://doi.org/10.1093/ofid/ofaa152
K. Wang, Z. Qiu, J. Liu, et al. Analysis of the clinical characteristics of 77 COVID -19 deaths. Scientific Reports, 10 (2020), p. 16384, doi: https://doi.org/10.1038/s41598-020-73136-7
P. R. Martins –Filho, C.S.S. Tavares, V.S. Santos. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. European journal of internal medicine, 76 (2020), pp. 97-99. doi: https://doi.org/10.1016/j.ejim.2020.04.043
Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin patients with COVID-19. J Clin Virol 2020; doi: https://doi.org/10.1016/j.jcv.2020.104370
Li H, Xiang X, Ren H, et al. Serum amyloid A is a biomarker of severe coronavirus disease and poor prognosis. J Infect 2020; doi: https://doi.org/10.1016/j.jinf.2020.03.035
Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe 2019; 15: 296-304. doi: https://doi.org/10.1183/20734735.0258-2019
Kamat IS, Ramachandran V. Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2020; 70: 538-542. doi: https://doi.org/10.1093/cid/ciz545
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18: 95-107. doi: https://doi.org/10.1016/s1473-3099(17)30592-3
Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011; 9: 107. doi: https://doi.org/10.1186/1741-7015-9-107
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID meta-analysis. Clin Chim Acta 2020; 505: 190-191. doi: https://doi.org/10.1016/j.cca.2020.03.004
Levi M, van der Poll T. Coagulation and sepsis. Thromb Res 2017; 149: 38-44. Doi: https://doi.org/10.1016/j.thromres.2016.11.007
Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a Review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 1-14 doi: https://doi.org/10.1080/22221751.2020.1746199
Lue W, Yu H, Gou J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020; 1-18. [Google Scholar]
Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 1023-1026. doi: https://doi.org/10.1111/jth.14810
Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct en leading to early death in sepsis. Front Immunol 2019, 10: 55. doi: https://doi.org/10.3389/fimmu.2019.00055
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrom Lancet 2014; 383: 1503-1516. doi: https://doi.org/10.1016/s0140-6736(13)61048-x
Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med 2020; 7: 1-6. doi: https://dx.doi.org/10.3389%2Ffmed.2020.00170
Pranata R, Lim MA, Huang 1, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression, Renin Angiotensin Aldosterone Syst 2020; 1-11. Doi: https://doi.org/10.1177/1470320320926899
Pranata R, Soeroto AY, Huang I, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tuberc Lung Dis. Epub ahead of print 28 may 2020 https://doi.org/10.5588/ijtld.20.0278
